Overview

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to characterize the early effects of ApoA-I synthesis with RVX000222 on coronary atherosclerotic disease when administered to patients with coronary artery disease and have a low HDL-C level, as assessed by Intravascular Ultrasound (IVUS) in addition to standard background therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Resverlogix Corp
Collaborator:
The Cleveland Clinic